Chinese pharma

CSPC Pharmaceutical Group is a leading integrated pharmaceutical enterprise in China, specializing in the research, development, manufacturing, and marketing of innovative medicines. The company maintains a strong market presence in therapeutic areas such as oncology, cardiovascular diseases, neurology, and anti-infectives. CSPC is notably recognized for its flagship product NBP (butylphthalide) for ischemic stroke and its advanced nanotechnology-based drug delivery systems. In recent years, the group has aggressively expanded into biologics and mRNA technology, successfully launching China's first domestically developed mRNA COVID-19 vaccine. With a robust pipeline of over 300 projects, CSPC continues to transition from a generic manufacturer to a global innovation-driven biopharmaceutical player.